ANVS
Annovis Bio Inc.
Company Overview
| Mkt Cap | $45.21M | Price | $4.13 |
| Volume | 1.04M | Change | +8.97% |
| P/E Ratio | -1.8 | Open | $3.77 |
| Revenue | -- | Prev Close | $3.79 |
| Net Income | $-24.6M | 52W Range | $1.11 - $6.37 |
| Div Yield | N/A | Target | $11.67 |
| Overall | 49 | Value | 60 |
| Quality | 23 | Technical | 66 |
No chart data available
About Annovis Bio Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.
Latest News
Canaccord Genuity Reaffirms Their Buy Rating on Annovis Bio (ANVS)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANVS | $4.13 | +9.0% | 1.04M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |